In Depth Symposia
2-5:30 pm
(IDS1) Cancer Survivorship
Moderators: Jacqueline N. Casillas, MD MSHS; Debra L. Friedman, MD MS
There are now approximately 300,000 childhood cancer survivors in the United States. Childhood cancer survivors are at risk for late effects and chronic health problems as a result of primary chemotherapy,
radiation, and surgery. The late effects of cancer treatment can include heart and lung dysfunction, secondary cancers, and psychosocial sequelae. The late effects occur several years to decades
after the previous cancer treatment, resulting in a high burden of chronic disease during young adult years. It is, therefore, critical for cancer survivors to receive long-term follow-up care to screen for late
effects during their pediatric, adolescent, and young adult years. Yet, the majority of childhood cancer survivors are not getting appropriatemlong-term follow-up care. National cooperative group efforts have provided best practice recommendations to improve the quality of care childhood cancer survivors receive.
Cancer Survivorship Care Planning
Noreen M. Aziz, MD PhD MPH; Melissa M. Hudson, MD
Screening for Medical Late Effects of Childhood Cancer Treatment
Debra L. Friedman, MD MS; Smita Bhatia, MD MPH
Optimizing Psychological Well-Being for Childhood Cancer Survivors and Their Families
Christopher J. Recklitis, PhD MPH
Assessing for Transition Readiness for Adolescent and Young Adult Childhood Cancer Survivors
Lisa A. Schwartz, PhD; Anna T. Meadows, MD
(IDS2) Sickle Cell Disease Research in the 21st Century
Moderator: Zora R. Rogers, MD
Sickle cell disease (SCD) is the most common hematologic disorder treated by pediatric hematologists/oncologists, usually with the same modalities (analgesics and hydration) employed for many
decades. Physicians have often questioned how the same single amino acid substitution can give rise to such variation in disease burden amongst patients. The significant advances made in the past
decade in our understanding of the basic pathophysiology of SCD are now being translated into improvements in clinical management. Speakers will discuss current survival and risk prediction, nitric oxide
biology and the hemolysis phenotype, stroke risk and management, available management strategies with hydroxyurea, chronic transfusion, and stem cell transplant. The future of gene therapy for SCD will be reviewed and National Institutes of Health (NIH) scientific staff will discuss how the realignment of their Sickle Cell Research Portfolio will support these new areas of research.
Realignment of the NIH Sickle Cell Research Portfolio: 2010 and Beyond
W. Keith Hoots, MD
Current Assessments of Survival and Risk Prediction in Sickle Cell Disease
Charles T. Quinn, MD MS
Nitric Oxide Biology and Hemolysis Phenotype in Sickle Cell Disease
Gregory J. Kato, MD
Stroke and Silent Stroke in Sickle Cell Disease: Prevention, Consequences, and Management
James F. Casella, MD
Sickle Cell Disease Modifying Therapies: Hydroxyurea and Chronic Transfusion
Zora R. Rogers, MD
Sickle Cell Disease Modifying Therapies: Stem Cell Transplant and Gene Therapy
Punam Malik, MD